Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.220
-0.070 (-1.63%)
Oct 16, 2026, 4:00 PM EDT - Market closed
Arbutus Biopharma Employees
Arbutus Biopharma had 19 employees as of December 31, 2025. The number of employees decreased by 25 or -56.82% compared to the previous year. That makes Arbutus Biopharma the 38,426th largest employer in the world and 5,558th in the United States.
Employees
19
Change (1Y)
-25
Growth (1Y)
-56.82%
Revenue / Employee
$9,564,211
Profits / Employee
$8,055,474
Market Cap
834.92M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 19 | -25 | -56.82% | 19 | 0 |
| Dec 31, 2024 | 44 | -29 | -39.73% | 44 | 0 |
| Dec 31, 2023 | 73 | -25 | -25.51% | 73 | 0 |
| Dec 31, 2022 | 98 | 11 | 12.64% | 96 | 2 |
| Dec 31, 2021 | 87 | 9 | 11.54% | 85 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Kura Oncology | 260 |
| Alumis | 239 |
| Rigel Pharmaceuticals | 174 |
| Monte Rosa Therapeutics | 173 |
| MoonLake Immunotherapeutics | 130 |
| Odyssey Therapeutics | 100 |
| ArriVent BioPharma | 77 |
| SpyGlass Pharma | 76 |
ABUS News
- 16 days ago - Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer - GlobeNewsWire
- 17 days ago - Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer - GlobeNewsWire
- 7 weeks ago - Arbutus Biopharma commences $230M modified Dutch Auction tender offer - TheFly
- 7 weeks ago - Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share - GlobeNewsWire
- 1 month ago - Arbutus Biopharma to repurchase $230M of shares through Dutch Auction - TheFly
- 1 month ago - Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer - GlobeNewsWire
- 2 months ago - Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Arbutus Biopharma Quarterly report: Q2 2026 - Filings